Top
image credit: Pxhere

Biotechs Bolstering Bank Accounts by Selling Stock This Week

March 25, 2021

Via: BioSpace
Category:

Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days, with Dutch biotechnology company LAVA Therapeutics leading the pact.

LAVA, a company harnessing expertise in bispecific gamma-delta T cell engagers to develop new cancer therapies, announced Wednesday the pricing of its IPO of 6,700,000 common shares at a public offering of $15.00 for each share. Under terms of the IPO, the company also granted a 30-day option to the underwriters to buy up to an additional 1,005,000 common shares at the same IPO price.

Read More on BioSpace